Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1

Imagem de Miniatura
Arquivos
art_BRUNETTO_Carboplatin_in_the_treatment_of_Ewing_sarcoma_Results_2015.PDF (215.67 KB)
Citações na Scopus
30
Tipo de produção
article
Data de publicação
2015
Editora
WILEY-BLACKWELL
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
BRUNETTO, Algemir L.
CASTILLO, Luis A.
PETRILLI, Antonio S.
MACEDO, Carla D.
BOLDRINI, Erica
COSTA, Cecilia
KIRST, Daniela
RODRIGUEZ-GALINDO, Carlos
PEREIRA, Waldir V.
Autor de Grupo de pesquisa
Brazilian Collaborative
Brazilian Collaborative Study Grp
Brazilian Soc Pediat Oncol-SOBOPE
Editores
Coordenadores
Organizadores
Citação
PEDIATRIC BLOOD & CANCER, v.62, n.10, p.1747-1753, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BackgroundLarge cooperative group studies have shown the efficacy of risk-adapted treatment for Ewing sarcoma. However, validation and local adaptation by National cooperative groups is needed. A multicenter protocol to determine the efficacy and safety of a risk-adapted intensive regimen was developed by the Brazilian cooperative group. ProcedurePatients <30 years old with Ewing sarcoma were eligible. Induction chemotherapy consisted of two cycles of ICE (ifosfamide, carboplatin, and etoposide) followed by two cycles of VDC (vincristine, doxorubicin, and cyclophosphamide), followed by local control. Patients with low risk (LR) disease (localized resectable with normal LDH) received 10 additional alternating courses of IE with VDC. For patients with high-risk (HR) disease (unresectable, pelvic, metastatic, or high LDH), two additional cycles of ICE were given. ResultsOne-hundred seventy five patients (39% metastatic) were enrolled. Fifty-two patients (29.7%) were LR and 123 (70.3%) were HR. Overall response rate at end of induction was 27.4%. Five-year event-free survival (EFS) and overall survival (OS) estimates were 51.4% and 54.4%, respectively. Patients with localized disease had better outcomes than patients with metastases (5-year EFS 67.9% vs. 25.5%, and 5-year OS 70.3% vs. 29.1%, respectively). On multivariate analysis, the presence of metastatic disease was the only prognostic factor (P<0.01). ConclusionThe VDC/ICE protocol was feasible, and considering the high tumor burden in our population, resulted in comparable results to those reported by cooperative groups in high-income countries. Further adaptation to maximize efficacy and minimize toxicity will be required. Pediatr Blood Cancer 2015;62:1747-1753. (c) 2015 Wiley Periodicals, Inc.
Palavras-chave
Ewing/PNET, metastatic disease, VDC/ICE
URI
https://observatorio.fm.usp.br/handle/OPI/19050
Referências
  1. Applebaum MA, 2011, CANCER-AM CANCER SOC, V117, P3027, DOI 10.1002/cncr.25840
  2. Bernstein M, 2006, ONCOLOGIST, V11, P503, DOI 10.1634/theoncologist.11-5-503
  3. Biswas B, 2013, PEDIATR BLOOD CANCER, V60, pE97, DOI 10.1002/pbc.24552
  4. Boriani S, 1999, P AN M AM SOC CLIN, V18, P556
  5. Cotterill SJ, 2000, J CLIN ONCOL, V18, P3108
  6. Dantonello TM, 2009, J CLIN ONCOL, V27, P1446, DOI 10.1200/JCO.2007.15.0466
  7. Esiashvili N, 2008, J PEDIAT HEMATOL ONC, V30, P425, DOI 10.1097/MPH.0b013e31816e22f3
  8. Friedrich P, 2014, CANCER-AM CANCER SOC, V120, P112, DOI 10.1002/cncr.28339
  9. Granowetter L, 2009, J CLIN ONCOL, V27, P2536, DOI 10.1200/JCO.2008.19.1478
  10. Grier HE, 2003, NEW ENGL J MED, V348, P694, DOI 10.1056/NEJMoa020890
  11. KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
  12. Luksch R, 2012, ANN ONCOL, V23, P2970, DOI 10.1093/annonc/mds117
  13. MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163
  14. MARINA NM, 1989, CANCER-AM CANCER SOC, V64, P1952, DOI 10.1002/1097-0142(19891101)64:9<1952::AID-CNCR2820640931>3.0.CO;2-W
  15. Meyer JS, 2008, PEDIATR BLOOD CANCER, V51, P163, DOI 10.1002/pbc.21596
  16. Milano GM, 2006, CANCER, V106, P1838, DOI 10.1002/cncr.21780
  17. Morris CD, 2010, J NATL COMPR CANC NE, V8, P731
  18. Oberlin O, 2001, BRIT J CANCER, V85, P1646, DOI 10.1054/bjoc.2001.2150
  19. Orr WS, 2012, ANN SURG ONCOL, V19, P3816, DOI 10.1245/s10434-012-2458-4
  20. Rodriguez-Galindo C, 2007, CANCER, V110, P375, DOI 10.1002/cncr.22821
  21. RUD NP, 1989, CANCER, V64, P1548, DOI 10.1002/1097-0142(19891001)64:7<1548::AID-CNCR2820640733>3.0.CO;2-W
  22. Sharib J, 2014, PEDIATR BLOOD CANCER, V61, P233, DOI 10.1002/pbc.24745
  23. Smith MA, 2010, J CLIN ONCOL, V28, P2625, DOI 10.1200/JCO.2009.27.0421
  24. SNEPPEN O, 1984, ACTA RADIOL ONCOL, V23, P159
  25. Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
  26. Veneroni L, 2013, PEDIAT BLOOD CANC, V60, P610
  27. Widhe B, 2000, J BONE JOINT SURG AM, V82, P67
  28. Womer RB, 2012, J CLIN ONCOL, V30, P4148, DOI 10.1200/JCO.2011.41.5703
  29. Wunder JS, 1998, J BONE JOINT SURG AM, V80A, P1020

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - ODS/03